猪口孝一
Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia. Int J Hematol.2014. 99: 41-52.
Establishment of MLL/AF4 transgenic mice with the phenotype of lymphoblastic leukemia or lymphoma. J Nippon Med Sch 2013: 80: 326-7.
Inhibition of S100A6 induces GVL effects in MLL/AF4-positive ALL in human PBMC-SCID mice. Bone Marrow Transplant. 2014:49:699-703.
Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia. Br J Haematol 2013: 163: 286-289.
Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib. Cancer Sci 2013 104: 1146-53.
Genes Chromosomes Cancer. 2017 Nov;56(11):800-809.
Amlexanox Downregulates S100A6 to Sensitize KMT2A/AFF1-Positive Acute Lymphoblastic Leukemia to TNFα Treatment. Cancer Res. 2017 Aug 15;77(16):4426-4433
Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy. Int J Clin Oncol. 2017 Oct;22(5):972-979.
D816V mutation in the KIT gene activation loop has a greater cell proliferative and anti-apoptotic ability than N822K mutation in core binding factor-acute myeloid leukemia. Ann Hematol. 2017 Oct;96(10):1641-1652.